Indium In-111 pentetate API Manufacturers

General Description:

Indium In-111 pentetate, identified by CAS number 135998-32-2, is a notable compound with significant therapeutic applications. Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

Indications:

This drug is primarily indicated for: Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Absorption:

The absorption characteristics of Indium In-111 pentetate are crucial for its therapeutic efficacy: After intrathecal administration, the radiopharmaceutical is absorbed from the subarachnoid space as described below, and the remainder flows superiorly to the basal cisterns within 2 to 4 hours and subsequently will be apparent in the Sylvian cisterns, the interhemispheric cisterns, and over the cerebral convexities. In normal individuals, the radiopharmaceutical will have ascended to the parasagittal region within 24 hours with simultaneous partial or complete clearance of activity from the basal cisterns and Sylvian regions. In contrast to air, the radiopharmaceutical does not normally enter the cerebral ventricles. Although the primary absorption of cerebrospinal fluid (CSF) into the blood stream occurs at the arachnoid villi, there is some evidence that a significant fraction of CSF is also absorbed across both the cerebral and spinal leptomeninges. Lesser quantities may also be absorbed across the ventricular ependyma. It is also generally held that these alternate routes of CSF absorption may assume primary importance when the major routes of the flow are pathologically obstructed. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Indium In-111 pentetate is an important consideration for its dosing schedule: Indium 111 decays by electron capture with a physical half-life of 67.9 hours. This determines the duration of action and helps in formulating effective dosing regimens.

Route of Elimination:

The elimination of Indium In-111 pentetate from the body primarily occurs through: Approximately 65% of the administered dose is excreted by the kidneys within 24 hours and this increases to 85% in 72 hours. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Mechanism of Action:

Indium In-111 pentetate functions by: Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Indium In-111 pentetate belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups, classified under the direct parent group Pentacarboxylic acids and derivatives. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Pentacarboxylic acids and derivatives subclass.

Categories:

Indium In-111 pentetate is categorized under the following therapeutic classes: Central Nervous System, Diagnostic Radiopharmaceuticals, Radioactive Diagnostic Agent, Radiopharmaceutical Activity. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.